VLA Limits for Intermediate Mass Black Holes in Three Globular Clusters

The observational evidence for central black holes in globular clusters has been argued extensively, and their existence has important consequences for both the formation and evolution of the cluster. Most of the evidence comes from dynamical arguments, but the interpretation is difficult, given the short relaxation times and old ages of the clusters. One of the most robust signatures for the existence of a black hole is radio and/or X-ray emission. We observed three globular clusters, NGC6093 (M80), NGC6266 (M62), and NGC7078 (M15), with the VLA in the A and C configuration with a 3-sigma noise of 36, 36 and 25 microJy, respectively. We find no statistically-significant evidence for radio emission from the central region for any of the three clusters. NGC6266 shows a 2-sigma detection. It is difficult to infer a mass from these upper limits due to uncertainty about the central gas density, accretion rate, and accretion model.Comment: 5 pages, accepted for publication in the Astronomical Journa

Ammonia Emissions in the United States, European Union, and China Derived by High-Resolution Inversion of Ammonium Wet Deposition Data: Interpretation with a New Agricultural Emissions Inventory (MASAGE_NH3)

We use the adjoint of a global 3-D chemical transport model (GEOS-Chem) to optimize ammonia $(NH_3)$ emissions in the U.S., European Union, and China by inversion of 2005–2008 network data for $NH^+_4$ wet deposition fluxes. Optimized emissions are derived on a 2° × 2.5° grid for individual months and years. Error characterization in the optimization includes model errors in precipitation. Annual optimized emissions are $2.8 Tg NH_3−N a^{−1}$ for the contiguous U.S., $3.1 Tg NH_3−N a^{−1}$ for the European Union, and $8.4 Tg NH_3−N a^{−1}$ for China. Comparisons to previous inventories for the U.S. and European Union show consistency $(\sim \pm 15$ in annual totals but some large spatial and seasonal differences. We develop a new global bottom-up inventory of $NH_3$ emissions (Magnitude And Seasonality of Agricultural Emissions model for NH3 (MASAGE_NH3)) to interpret the results of the adjoint optimization. MASAGE_NH3 provides information on the magnitude and seasonality of $NH_3$ emissions from individual crop and livestock sources on a 0.5° × 0.5° grid. We find that U.S. emissions peak in the spring in the Midwest due to corn fertilization and in the summer elsewhere due to manure. The seasonality of European emissions is more homogeneous with a well-defined maximum in spring associated with manure and mineral fertilizer application. There is some evidence for the effect of European regulations of $NH_3$ emissions, notably a large fall decrease in northern Europe. Emissions in China peak in summer because of the summertime application of fertilizer for double cropping.Engineering and Applied Science

Wide-field global VLBI and MERLIN combined monitoring of supernova remnants in M82

From a combination of MERLIN (Multi-Element Radio-Linked Interferometer Network) and global VLBI (Very Long Baseline Interferometry) observations of the starburst galaxy M82, images of 36 discrete sources at resolutions ranging from ~3 to ~80 mas at 1.7 GHz are presented. Of these 36 sources, 32 are identified as supernova remnants, 2 are HII regions, and 3 remain unclassified. Sizes, flux densities and radio brightnesses are given for all of the detected sources. Additionally, global VLBI only data from this project are used to image four of the most compact radio sources. These data provide a fifth epoch of VLBI observations of these sources, covering a 19-yr time-line. In particular, the continued expansion of one of the youngest supernova remnants, 43.31+59.3 is discussed. The deceleration parameter is a power-law index used to represent the time evolution of the size of a supernova remnant. For the source 43.31+59.3, a lower limit to the deceleration parameter is calculated to be 0.53+/-0.06, based on a lower limit of the age of this source.Comment: 31 pages, 12 figures, 7 table

Incremental testing of the Community Multiscale Air Quality (CMAQ) modeling system version 4.7

This paper describes the scientific and structural updates to the latest release of the Community Multiscale Air Quality (CMAQ) modeling system version 4.7 (v4.7) and points the reader to additional resources for further details. The model updates were evaluated relative to observations and results from previous model versions in a series of simulations conducted to incrementally assess the effect of each change. The focus of this paper is on five major scientific upgrades: (a) updates to the heterogeneous N<sub>2</sub>O<sub>5</sub> parameterization, (b) improvement in the treatment of secondary organic aerosol (SOA), (c) inclusion of dynamic mass transfer for coarse-mode aerosol, (d) revisions to the cloud model, and (e) new options for the calculation of photolysis rates. Incremental test simulations over the eastern United States during January and August 2006 are evaluated to assess the model response to each scientific improvement, providing explanations of differences in results between v4.7 and previously released CMAQ model versions. Particulate sulfate predictions are improved across all monitoring networks during both seasons due to cloud module updates. Numerous updates to the SOA module improve the simulation of seasonal variability and decrease the bias in organic carbon predictions at urban sites in the winter. Bias in the total mass of fine particulate matter (PM<sub>2.5</sub>) is dominated by overpredictions of unspeciated PM<sub>2.5</sub> (PM<sub>other</sub>) in the winter and by underpredictions of carbon in the summer. The CMAQv4.7 model results show slightly worse performance for ozone predictions. However, changes to the meteorological inputs are found to have a much greater impact on ozone predictions compared to changes to the CMAQ modules described here. Model updates had little effect on existing biases in wet deposition predictions

Research Progress Reports: Fruit and Vegetable Processing and Technology Division, Department of Horticulture [1967]

Evaluation of snap bean varieties for processing / Wilbur A. Gould and William Hildebolt -- Evaluation of various grape cultivars for processing. I. Table wines ; Recommended fruit varieties for canning and freezing / J. F. Gallander -- Evaluation of tomato varieties for processing / W. A. Gould, J. R. Geisman, C. S. Parrott, J. H. McClelland and W. N. Brown -- The effect of different levels of sugar and acid on the quality of apple fruit juice blends / James Gallander and Harold Stammer -- Epidermal sloughing of snap beans as influenced by processing variables / William Hildebolt and W. A. Gould -- Effect of stannous chloride on the color of glass packed kraut / J. R. Geisman -- Proteins and enzymes in the apple fruit in relation to variety and maturation ; Proteins and enzymes in tomato fruits / Robert L. Clements -- Effect of food additives on quality of canned tomatoes / Wilbur A. Gould -- Effects of selective herbicides on the composition and quality of tomatoes / W. A. Gould, J. R. Geisman, E. K. Alban and John Deppen -- Trace levels of pesticide residues in agricultural commodities in marketing channels / W. A. Gould, J. R. Geisman, E. K. Alban, John Deppen, and P. van Pottlesberghe -- Removal of DDT residues by unit operations in preparing and processing spinach / J. R. Geisman, John Deppen and Benita Yao -- The use of chlorine dioxide in handling and holding mechanically harvested tomatoes / J. R. Geisman, Winston D. Bash, Edwin Schmidt, Jr., Linda Hamrick and W. A. Gould -- Effect of mechanical harvesting and handling of tomatoes on quality of canned tomatoes / Wilbur A. Gould, J. R. Geisman, Edwin Schmidt, Jr., John McClelland and W. N. Brow

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved